Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor Optune, a device that delivers tumor treating fields NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients Margetuximab for the treatment of breast and gastroesophageal cancers Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor Tebotelimab, a tetravalent IgG4 monoclonal antibody Retifanlimab that inhibits interactions between PD-1 and its ligands ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor ZL-1201, a humanized IgG4 monoclonal antibody Efgartigimod to reduce disease-causing immunoglobulin G antibodies ZL-1102, a human nanobody targeting interleukin- 17A KarXT for the treatment of psychiatric and neurological conditions ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring ZL-2314, an investigational inhibitor of double-mutant EGFR harboring and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.